Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation
Fig 2
Acute daily administration of SR9009 does not induce short-term tolerance (A) Schematic of experimental paradigm to assess short-term tolerance in response to the REV-ERB agonist SR9009. Mice were injected with SR9009 (i.p. 100mg kg-1) at ZT6 on three consecutive days in order to assess tolerance. (B) SR9009 increased wakefulness, but only reached significance on day 3 (p<0.05), decreased SWS on days 2 and 3 (p<0.05), and decreased REM on day 3 (C) Overall, SR9009 increased SWS latency (F(1,5) = 7.7, p<0.05, only significant on Day 2 p = 0.02). SR9009 increased REM sleep latency, reaching significance on all days tested (F(1,5) = 183.4, p<0.0001, Day 1 p = 0.0004, Day 2 p<0.0001, and Day 3 p<0.0001). *P<0.05, *** P<0.005.